CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 2, 2011, Pages 160-164

  Mulugeta, Ezra ^a,b   Londos, Elisabet ^c,d   Ballard, Clive ^b   Alves, Guido ^a   Zetterberg, Henrik ^e   Blennow, Kaj ^e   Skogseth, Ragnhild ^f   Minthon, Lennart ^c,d   Aarsland, Dag ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Department of Clinical Sciences   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN 38; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; ASSAY; CEREBROSPINAL FLUID; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTI ARRAY KIT ASSAY; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; NEUROPSYCHOLOGICAL TESTS; NORWAY; PARKINSON DISEASE; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEX CHARACTERISTICS; SWEDEN; TAU PROTEINS;

EID: 78751521471     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.199398     Document Type: Article

References (36)

1. Bostrom F, Jonsson L, Minthon L, et al. Patients with dementia with Lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21:150-4.
2. Bostrom F, Jonsson L, Minthon L, et al. Patients with Lewy body dementia use more resources than those with Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:713-19. (Pubitemid 47322596)
3. Williams MM, Xiong C, Morris JC, et al. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology 2006;67:1935-41. (Pubitemid 44967367)
4. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005;66:633-7.
5. Rongve A, Skogseth R, Aarsland D. Risk of nursing home placement in dementia with Lewy bodies. ICAD 2009, Vienna, Austria. Journal of the Alzheimer's Association 2009.
6. Tiraboschi P, Salmon DP, Hansen LA, et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 2006;129:729-35.
7. Aarsland D, Kurz M, Beyer M, et al. Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers. Dement Geriatr Cogn Disord 2008;25:195-205.
8. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430:631-9.
9. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53.
10. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001;24:87-97.
11. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812-19.
12. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-93.
13. Blennow K. CSF biomarkers for mild cognitive impairment. J Intern Med 2004;256:224-34. (Pubitemid 39222991)
14. Bibl M, Mollenhauer B, Esselmann H, et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006;129:1177-87.
15. Bibl M, Mollenhauer B, Lewczuk P, et al. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 2007;12:671-80.
16. Welge V, Fiege O, Lewczuk P, et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 2009;116:203-12.
17. Aarsland D, Rongve A, Nore SP, et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord 2008;26:445-52.
18. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613-8.
19. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72.
20. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44. (Pubitemid 14076461)
21. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-37.
22. Fahn S, Elton R, Committee. M. o. t.U.D. Unified Parkinson's Disease Rating Scale. Florham Park, NJ: MacMillan Health Care Information, 1987.
23. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14. (Pubitemid 24382728)
24. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004;62:181-7.
25. Walker MP, Ayre GA, Cummings JL, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology 2000;54:1616-25.
26. Bateman RJ, Wen G, Morris JC, et al. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007;68:666-9. (Pubitemid 46667813)
27. Blennow K, Wallin A, Agren H, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-45.
28. Vanderstichele H, De Vreese K, Blennow K, et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006;44:1472-80.
29. Consensus Report of the Working Group on "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-16.
30. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSeADRDA criteria. Lancet Neurol 2007;6:734-46.
31. Ballard C, Jones EL, Londos E, et al. Alpha-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. Int Psychogeriatr 2009:1-7.
32. Fujishiro H, Ferman TJ, Boeve BF, et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol 2008;67:649-56.
33. Dickson DW, Fujishiro H. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2008;70:2087-8.
34. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-4.
35. Koopman K, Le Bastard N, Martin JJ, et al. Improved discrimination of autopsyconfirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int 2009;55:214-18.
36. Mori H. Pathological substrate of dementia in Parkinson's diseased - its relation to DLB and DLBD. Parkinsonism Relat Disord 2005;11(Suppl 1):S41-5.